Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Intervalo de año de publicación
1.
Panminerva Med ; 52(2 Suppl 1): 75-80, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20657539

RESUMEN

To provide an overview of molecular and cellular processes involved in erectile dysfunction (ED) with emphasis on circulating endothelial progenitor cells (EPC) and discuss possible nutraceutical means of intervention. A review of literature on Pubmed related to EPC and ED was conducted. Patients with ED appear to possess a reduced number of circulating EPC, which is associated with poor endothelial function possibly as a result of underlying low-grade inflammation. Several studies support the possibility of improving erectile function by inhibition of inflammation as well as administration of various stem cell types. One particularly interesting approach is nutraceutical supplementation to increase circulating EPC, as demonstrated in the product Stem-Kine. Interventions aimed at increasing circulating EPC may have potential in treatment of vascular ED.


Asunto(s)
Células Endoteliales/citología , Disfunción Eréctil/tratamiento farmacológico , Células Madre/citología , Proteína C-Reactiva/metabolismo , Factor Estimulante de Colonias de Granulocitos y Macrófagos/metabolismo , Movilización de Célula Madre Hematopoyética/métodos , Humanos , Inflamación , Masculino , Ciencias de la Nutrición , Pene/patología , Resultado del Tratamiento
2.
P. R. health sci. j ; 23(2): 115-118, Jun. 2004.
Artículo en Inglés | LILACS | ID: lil-390793

RESUMEN

A series of seven cases are presented in which intravenous vitamin C has been used as antineoplastic agent in the treatment of different types of cancers. The cancers cases reviewed are the following: Renal cell carcinoma (2), Colorectal cancer (1), Pancreatic cancer (1), Non-Hodgkin's lymphoma (2) and breast cancer (1). Toxic reactions were not observed at these high doses of intravenous Vitamin C. All patients were prescreened for Glucose 6--phosphate dehydrogenase deficiency before administering intravenous Vitamin C in order to prevent hemolysis


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Ácido Ascórbico/administración & dosificación , Antineoplásicos/administración & dosificación , Antioxidantes/administración & dosificación , Neoplasias/tratamiento farmacológico , Ácido Ascórbico/efectos adversos , Antineoplásicos/efectos adversos , Antioxidantes/efectos adversos , Inyecciones Intravenosas , Resultado del Tratamiento
3.
P. R. health sci. j ; 22(3): 287-290, Sept. 2003.
Artículo en Inglés | LILACS | ID: lil-355994

RESUMEN

High dose intravenous(i.v.) ascorbic acid (AA) has been used as therapy for infectious disease from bacterial and viral origin and adjuvant therapy for cancer. In this publication we describe a clinical protocol that has been developed over the past twenty years utilizing high dose i.v. AA as therapy for cancer. This includes principles of treatment, rationale, baseline workup, infusion protocol, precautions and side effects.


Asunto(s)
Humanos , Ácido Ascórbico/administración & dosificación , Antiinfecciosos , Ácido Ascórbico/efectos adversos , Ácido Ascórbico/farmacología , Ácido Ascórbico/uso terapéutico , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Protocolos Clínicos , Relación Dosis-Respuesta a Droga , Infecciones Bacterianas/tratamiento farmacológico , Infusiones Intravenosas , Neoplasias/tratamiento farmacológico , Virosis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA